Work

Cost Analysis of Raltegravir Versus Atazanavir/r or Darunavir/r for Treatment-naive Adults With Hiv-1 Infection in the United States

Year: 2016

Type: article

Source: Value in Health

DOI: 10.1016/j.jval.2016.03.1207

Authors: A.E. Davis, A.J. Brogan, B.B. Goodwin

Institutions: RTI Health Solutions, Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2405915239

FWCI:

Cites:

Cited by:

Related to: 10